Free Trial
NASDAQ:CMMB

Chemomab Therapeutics (CMMB) Stock Price, News & Analysis

Chemomab Therapeutics logo
$3.32 +0.04 (+1.22%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$3.25 -0.07 (-2.08%)
As of 04:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Chemomab Therapeutics Stock (NASDAQ:CMMB)

Advanced

Key Stats

Today's Range
$3.11
$3.37
50-Day Range
$2.50
$3.83
52-Week Range
$2.39
$9.84
Volume
186,676 shs
Average Volume
273,892 shs
Market Capitalization
$17.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.50
Consensus Rating
Hold

Company Overview

Chemomab Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

CMMB MarketRank™: 

Chemomab Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 577th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Chemomab Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Chemomab Therapeutics has a consensus price target of $26.50, representing about 698.2% upside from its current price of $3.32.

  • Amount of Analyst Coverage

    Chemomab Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Chemomab Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Chemomab Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Chemomab Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Chemomab Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Chemomab Therapeutics has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Chemomab Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.04% of the float of Chemomab Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Chemomab Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Chemomab Therapeutics has recently increased by 14.75%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Chemomab Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Chemomab Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.04% of the float of Chemomab Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Chemomab Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Chemomab Therapeutics has recently increased by 14.75%, indicating that investor sentiment is decreasing significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Chemomab Therapeutics' insider trading history.
    Receive CMMB Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    CMMB Stock News Headlines

    Gold surges past $3,600 … but this has beat gold by 1,000x
    Gold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real opportunity isn’t in coins or bullion. In every major gold rally of the past 50 years, there’s been another investment that has delivered dramatically higher returns.tc pixel
    See More Headlines

    CMMB Stock Analysis - Frequently Asked Questions

    Chemomab Therapeutics' stock was trading at $7.24 at the beginning of the year. Since then, CMMB stock has decreased by 54.1% and is now trading at $3.32.

    Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) issued its earnings results on Thursday, August, 14th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.44.

    Chemomab Therapeutics shares reverse split before market open on Tuesday, August 26th 2025.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

    Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Chemomab Therapeutics investors own include Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW), NVIDIA (NVDA), Meta Platforms (META) and Adobe (ADBE).

    Company Calendar

    Last Earnings
    8/14/2025
    Today
    10/20/2025
    Next Earnings (Estimated)
    11/13/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:CMMB
    CIK
    1534248
    Fax
    N/A
    Employees
    20
    Year Founded
    2010

    Price Target and Rating

    High Price Target
    $28.00
    Low Price Target
    $25.00
    Potential Upside/Downside
    +698.2%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.33
    Research Coverage
    3 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($2.36)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$13.94 million
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    -94.71%
    Return on Assets
    -76.53%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    7.42
    Quick Ratio
    7.42

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $2.87 per share
    Price / Book
    1.16

    Miscellaneous

    Outstanding Shares
    5,170,000
    Free Float
    4,557,000
    Market Cap
    $17.16 million
    Optionable
    Not Optionable
    Beta
    0.57
    Analysts Agree—These Gold Picks Outshine the Rest Cover

    Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

    Get This Free Report

    This page (NASDAQ:CMMB) was last updated on 10/20/2025 by MarketBeat.com Staff
    From Our Partners